Solid Biosciences Inc. (SLDB) Social Stream



Solid Biosciences Inc. (SLDB): $0.62

0.04 (+7.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLDB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Solid Biosciences Inc (SLDB) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering SLDB.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 6 $17 $5.5 $10.3 $1.21 751.24%
2022-03-14 5 $17 $5.5 $10.3 $1.21 751.24%
2022-03-15 4 $17 $5 $10.2 $1.21 742.98%

The Trend in the Analyst Price Target


SLDB's average price target has moved down $0.97 over the prior 47 weeks.

SLDB reports an average of 260.97% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-22 8 20 2 11.80 4.020 193.53%
2021-06-05 7 20 2 9.67 3.620 167.13%
2021-07-24 8 20 2 9.14 2.780 228.78%
2021-09-11 8 20 2 9.14 2.740 233.58%
2022-03-15 4 17 5 10.20 0.985 935.53%

SLDB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.5 2 0 1 1 1 4

The Trend in the Broker Recommendations


Over the past 22 months, SLDB's average broker recommendation rating improved by 0.21.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SLDB as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, Solid Biosciences Inc's upside potential (average analyst target price relative to current price) is greater than 392.4% of them.
  • Solid Biosciences Inc's variance in analysts' estimates is lower than -278.57% of all US stocks.
  • In terms of how Solid Biosciences Inc fares relative to Healthcare stocks, note that its average analyst price target is higher than 64.54% of that group.
  • To contextualize these metrics, consider that out of Healthcare stocks, Solid Biosciences Inc's number of analysts covering the stock is higher than 131.29% of them.

Stocks similar to Solid Biosciences Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SABS, PTE, and PSTX.

Make investment decisions regarding SLDB using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3767 seconds.